WAIKOLOA, HAWAII -- Clobetasol propionate spray 0.05% resulted in dramatic clinical improvement with a low rate of adverse events and excellent acceptance in patients with moderate to severe generalized psoriasis in the largest community-based trial ever conducted in psoriasis.
Results of the 2,488-patient Clobex Spray Community-Based Research Assessment (COBRA) trial advance psoriasis therapy to the threshold of a breakthrough era, said Dr. John Koo at the annual Hawaii Dermatology Seminar sponsored by Skin Disease Education Foundation. For patients with moderate to severe generalized disease, there is now the prospect of entirely topical short-term and maintenance ...